Core J: Virology and Molecular Biomarkers

项目摘要/摘要 病毒学和分子生物标志物(VMB)核心(核心J)提供了最先进的资源来催化 基础、翻译、临床和行为HIV/SIV研究，以支持Emory CFAR的使命。《核心》 由三个高度协作的单位组成，资源和专门知识相辅相成。《翻译》 病毒学单位(TVU)，开发和实施病毒定量分析，主要支持非人类灵长类 (NHP)艾滋病发病机制、预防、治疗和治愈研究的模型。CLIA/CAP认证的临床 病毒学单位(CVU)，提供病毒学和分子诊断分析，用于临床、翻译和 HIV感染、性传播感染(STI)、混合感染和相关综合征的行为研究。 病毒储存库单位(VRU)开发和实施量化病毒储存库的分析方法 支持治疗研究的抗逆转录病毒疗法(ART)。VMB Core提供创新、标准化、高性能 吞吐量病毒定量分析，灵活地适应了HIV/SIV研究人员在不断演变的需求 作为培训分子病毒学分析的早期研究人员的资源。 核心通过开发、验证和 提供：1)艾滋病毒、SIV和SIV的标准化血浆病毒载量分析；2)细胞相关DNA和 SIV和HIV的RNA检测；3)HIV相关联合感染的分子诊断检测(乙肝病毒、丙型肝炎病毒、 CMV)和性传播感染；4)非标准样本中的HIV/SIV定量检测；以及5)分子检测 在抗逆转录病毒疗法下测量病毒库。Core通过添加VRU来扩展其服务，以支持 艾滋病毒治愈研究，包括建立、维持和根除持久的 在抗逆转录病毒治疗下潜伏感染细胞。在下一个项目期间，VMB Core将进一步扩大范围和整体 执行所提供的分析和服务，并利用Illumina MiSeq深度测序平台 描述病毒整合部位、病毒进化对新疗法的反应，以及 生殖器/肠道微生物群与艾滋病毒传播/发病机制中心将继续在#年开展培训活动。 分子病毒学技术和基因分析，提供专家咨询，扩大机会 对于利益相关者通过以下具体目标参与： 目标1.扩大翻译病毒学股的能力，以提供更广泛的分析以支持 非霍奇金淋巴瘤中SIV/SIV的发病机制及防治研究 目的2.提供艾滋病毒人体研究和临床试验所需的已建立的和新的分析方法 通过CLIA认证的临床病毒学单位的定制临床测试。 目的3.通过已建立的和新的病毒检测方法，支持在NHP中治愈研究的增长 在ART抑制的储存库中，在病毒储存库单元中感染SIV/SHV的NHP。

PROJECT SUMMARY/ABSTRACT The Virology and Molecular Biomarkers (VMB) Core (Core J) provides state-of-the-art resources to catalyze basic, translational, clinical, and behavioral HIV/SIV research in support of Emory CFAR’s mission. The Core comprises three highly collaborative units with complementary resources and expertise. The Translational Virology Unit (TVU), develops and implements viral quantitative assays supporting primarily nonhuman primate (NHP) models of AIDS pathogenesis, prevention, therapy, and cure research. The CLIA/CAP-certified Clinical Virology Unit (CVU), provides virologic and molecular diagnostic assays for clinical, translational, and behavioral studies of HIV infection, sexually transmitted infections (STI), co-infections, and related syndromes. The Viral Reservoirs Unit (VRU) develops and implements assays that quantify the viral reservoir on antiretroviral therapy (ART) to support cure research. The VMB Core provides innovative, standardized, high throughput viral quantitative assays, nimbly adapts to the needs of HIV/SIV researchers in an ever-evolving field, and serves as a resource for training early-stage investigators in molecular virologic assays. The Core effectively responds to the needs of an evolving field through the development, validation, and provision of: 1) standardized plasma viral load assays for HIV, SIV, and SHIV; 2) cell-associated DNA and RNA assays for SIV and HIV; 3) molecular diagnostic assays for HIV-associated co-infections (HBV, HCV, CMV) and STIs; 4) HIV/SIV quantitative assays in non-standard specimens; and 5) molecular assays to measure the viral reservoir under ART. The Core expanded its services with the addition of the VRU to support HIV cure research, including the establishment, maintenance, and eradication of the persistent reservoir of latently infected cells under ART. In the next project period, the VMB Core will further the range and overall performance of provided assays and services and leverage the Illumina MiSeq deep sequencing platform to characterize virus integration sites, viral evolution in response to new therapies, and the relationship of the genital/gut microbiomes with HIV transmission/pathogenesis. The Core will continue training activities in molecular virological techniques and gene assays, providing expert consultation, and expanding opportunities for stakeholder engagement through these specific aims: Aim 1. Expand the capacity of the Translational Virology Unit to provide a greater range of assays to support studies of pathogenesis, prevention, and therapy of SIV/SHIV in NHPs. Aim 2. Provide established and novel assays required for HIV human subjects research and clinical trials through customized clinical testing in the CLIA-certified Clinical Virology Unit. Aim 3. Support the growth in cure studies in NHPs through established and novel assays measuring the virus reservoir in ART-suppressed, SIV/SHIV-infected NHP in the Viral Reservoirs Unit.